Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Short position
Mesoblast (ASX:MSB) has 7.57% of its shares on issue reported as short positions as of 5 Oct 2026, or about 98,260,040 shares. Over the past 30 days that figure has risen 0.64 percentage points, and over 90 days it has fallen 0.78 percentage points. Its highest recorded short interest was 11.00% in October 2015. MSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Mesoblast (MSB) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in USD, the reporting currency
- Revenue
- 120.3Mvs 17.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −57.5Mvs −102.1M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −0.044T (source: Derived: trailing 12 months at year end)vs −0.085 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- n/mFY
- EPS YoY
- n/aFY
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 86.1%
- Operating margin
- −42.6%
- Net margin
- −47.8%
- FCF margin
- −37.2%
- ROE
- −9.9%
- ROA
- −7.4%
- FCF conversion
- n/a
- Net debt (excl. leases)
- USD 71.8M
- Net debt / EBITDA
- n/a
- Current ratio
- 2.4×
- Interest cover
- −2.6×
- Cash dividends paid / net profit
- n/a
- Market cap
- $2.59B
- P/E
- n/a (reports in USD)
- P/B
- n/a (reports in USD)
Ratios use the reporting currency (USD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 120.3M | 17.2M | 5.9M | 7.5M |
| Gross profit | 103.6M | 12.1M | 5.9M | 7.5M |
| Operating income | −51.3M | −62.4M | −56.2M | −69.3M |
| EBITDA | −37.0M | −80.1M | −65.1M | −62.7M |
| EBIT | −37.0M | −80.1M | −65.1M | −62.7M |
| Interest expense | 19.9M | 21.8M | 23.0M | 19.4M |
| Pretax income | −56.9M | −101.8M | −88.1M | −82.1M |
| Tax | 613.0K | 330.0K | −191.0K | −212.0K |
| NPAT | −57.5M | −102.1M | −88.0M | −81.9M |
| Net interest income | −18.0M | −19.0M | −23.0M | −18.6M |
| EPS basic | −0.044T (source: Derived: trailing 12 months at year end) | −0.085 | −0.089 | −0.11 |
| EPS diluted | −0.044T (source: Derived: trailing 12 months at year end) | −0.085 | −0.089 | −0.11 |
| Shares | 1.30B | 1.28B | 1.14B | 858.2M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- MSB Annual Financial Results and Operational UpdateAnnual Report27 Aug 2026via asx_announcements
- Annual Financial Results PresentationAnnual Report27 Aug 2026via asx_announcements
- Preliminary Final Report including Appendix 4EAnnual Results27 Aug 2026via asx_announcements
- Mesoblast 2026 Full Year Financial Results WebcastFull Year Results24 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Year Report and Accounts (including Appendix 4D)Half Year Results27 Feb 2026via asx_announcements
- Corporate Presentation and Half Year Financial ResultsHalf Year Results27 Feb 2026via asx_announcements
- Mesoblast 2026 Half Year Financial Results WebcastHalf Year Results20 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
Showing 10 of 169 reports